NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症治療的基因學的全球市場(2021年∼2028年)

Global Genomics in Cancer Care Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008246
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
癌症治療的基因學的全球市場(2021年∼2028年) Global Genomics in Cancer Care Market - 2021-2028
出版日期: 2021年05月27日內容資訊: 英文 180 Pages
簡介

全球癌症治療基因組學市場成長的主要因素有越來越多的診斷、個性化醫療以及藥物發現和開發應用。癌症發病率增加、早期疾病診斷意識提高、人口老齡化加劇和技術進步等因素正在推動市場增長。

還有與癌症治療相關的生物技術的進步已成為市場增長的主要驅動力。隨著癌症患者人數的增加,對癌症的高級診斷和治療方法的需求將會增加,預計市場將變得更加活躍。此外,新產品的推出和各大公司之間高效的戰略合作也將帶動市場。然而,與基因組學設備相關的高價格可能會在預測期內阻礙市場的增長。

本報告提供全球癌症治療的基因學市場的相關調查,提供市場機會和影響,成長及阻礙因素,產品·用途·技術·最終用途·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球癌症治療的基因學市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球癌症治療的基因學市場-市場定義和概要

第3章 全球癌症治療的基因學市場-摘要整理

  • 各產品的市場明細
  • 各用途的市場明細
  • 各技術市場明細
  • 各最終用途市場明細
  • 各地區的市場明細

第4章 全球癌症治療的基因學市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球癌症治療的基因學市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球癌症治療的基因學市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 當前的 COVID-19 市場情景
    • COVID-19後的市場方案或未來情景
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 疫情期間與市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球癌症治療的基因學市場-各產品

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 設備
    • 簡介
    • 市場規模分析及與前一年同期比較成長分析(2020-2028)
  • 消耗品
  • 服務

第8章 全球癌症治療的基因學市場-各用途

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 診斷
    • 簡介
    • 市場規模分析及與前一年同期比較成長分析(2020-2028)
  • 個人化醫療
  • 藥物研發與開發
  • 調查

第9章 全球癌症治療的基因學市場-各技術

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 基因序列測定
    • 簡介
    • 市場規模分析及與前一年同期比較成長分析(2020-2028)
  • PCR
  • 微陣列
  • 與核酸的開採精製

第10章 全球癌症治療的基因學市場-各終端用戶

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 醫院
    • 簡介
    • 市場規模分析及與前一年同期比較成長分析(2020-2028)
  • 診所
  • 門診病人手術中心

第11章 全球癌症治療的基因學市場-各地區

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 北美
    • 簡介
    • 主要每個地區的動態
    • 各產品:市場規模分析,及與前一年同期比較成長分析
    • 各用途:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各最終用途:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 主要每個地區的動態
    • 各產品:市場規模分析,及與前一年同期比較成長分析
    • 各用途:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各最終用途:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 主要每個地區的動態
    • 各產品:市場規模分析,及與前一年同期比較成長分析
    • 各用途:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各最終用途:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 主要每個地區的動態
    • 各產品:市場規模分析,及與前一年同期比較成長分析
    • 各用途:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各最終用途:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 主要每個地區的動態
    • 各產品:市場規模分析,及與前一年同期比較成長分析
    • 各用途:市場規模分析,及與前一年同期比較成長分析
    • 各技術:市場規模分析,及與前一年同期比較成長分析
    • 各最終用途:市場規模分析,及與前一年同期比較成長分析

第12章 全球癌症治療的基因學市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第13章 全球癌症治療的基因學市場-企業簡介概要

  • Roche Diagnostics
    • 企業概要
    • 產品系列·概要
    • 要點
    • 財務概要
  • AstraZeneca PLC
  • Illumina, Inc
  • Affymetrix
  • Agilent Technologies
  • Cancer Genetics Inc.
  • Beckman Coulter Inc.
  • Bio-Rad Labs
  • Danaher Corporation
  • Sigma Aldrich Corporation

第14章 全球癌症治療的基因學市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global genomics in cancer care market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Genomics plays a crucial role in precision medicine and drug development for cancer. Identifying Cancer-causing mutations is very crucial, and Genomics plays a vital role in achieving this. Genetic mutations do not have such a central role in all cancer diagnoses, but even if they don't, their presence or absence might change how each person's cancer is described.

At the Netherlands Cancer Institute, each person with metastatic cancer must use their cancer genome sequencing. Its database now includes genomic-sequencing data from around 5,000 people. For people with a cancer mutation that an achievable therapy can target, there is no question that cancer-genome sequencing directs to better outcomes and survival.

Market Dynamics

The genomics in cancer care market growth is driven by the increasing application in diagnostics, personalized medicine, and drug discovery & development. Factors such as rising incidence of cancer, increasing awareness about early disease diagnosis, growing geriatric population, and advancement in technology drive the market growth.

Incresing geriatric population and advancement in technology will drive the market growth

According to the Global Health and Aging report published by the World Health Organization, the number of people aged 65 years or greater is expected to increase from a predicted 524 million in 2010 to about 1.5 billion by 2050, with a significant percentage of increase in emerging economies. Primary chronic diseases such as cancer have had the most significant impact on the geriatric population, especially in high-income countries. Thus, the growing prevalence of diseases in the increasing geriatric population is expected to propel the growth of the genomic cancer care market in the forecast period.

Detection of cancer at an initial stage significantly raises the possibilities for survival. Creating awareness to promote early diagnosis and screening are the essential steps responsible for early detection of disease comprising breast, blood, colorectal, lung, and cervical, among others. Recognizing likely warning symptoms of cancer and taking active measures is necessary for early diagnosis. Greater appreciation of probable signs of the disease amongst physicians, nurses, and other healthcare providers and the general public would positively influence the survival rate and help increase the genomics in cancer care market demand.

The rising in cancer and biotechnological advancements related to cancer care

The rise in cancer and biotechnological advancements related to cancer care is a significant factor in propelling the market growth. According to Globocan 2020, an expected 19,292,789 new cancer cases were diagnosed worldwide, with approximately 9,958,133 deaths due to cancers. In addition, as per the International Agency for Research on Cancer, the proportion of cancer cases is expected to grow to 27.5 million new cases and 16.3 million deaths worldwide by 2040. The rising incidence of cancer cases is anticipated to drive the need for superior diagnostics and treatment options for cancers, which is supposed to boost the market. Also, the launch of new products and efficient strategic collaborations between key players is expected to drive the market. For instance, in Sep 2020, Thermo Oncamine Precision Assay and Fisher Scientific's Ion Torrent Genexus System were selected by the LC-SCRUM-Asia, a leading cancer genomic screening program, to develop precision medicine in Asia. Thus, because of the factors mentioned above, the genomic in the cancer care market is predicted to register significant growth over the forecast period globally.

High price associated with genomics devices will hamper the market growth

However, the high price associated with genomics devices may create restraints in the growth of genomics in the cancer care market in the forecast period..

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, in May 2020, Genomics England partnered with the genomic consortium, directed by the University of Edinburgh. This partnership intended to identify and investigate the whole genome sequences of approximately 35,000 COVID-19 infected patients with symptoms varying from mild to severe. The Genomics England, the Department of Health and Social Care, and the National Institute for Health Research granted about GBP 28 million for the project. Illumina was involved in sequencing all 35,000 genomes. Hence, the genome sequencing segment is expected to grow during the COVID-19 pandemic in the forecast period.

Segment Analysis

By technology, the genomics in cancer care market is classified into genome sequencing, pcr, microarray, nucleic acid extraction and purification.

Genome Sequencing segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Developing technology related to genome sequencing is anticipated to fuel market growth. Next-Generation sequencing is a novel method having wide application in oncology. DNA sequencing and RNA sequencing helps in detecting and analyzing the modifiers, mutation analysis, and pharmacogenetics of biopsy.

According to the research article published in Trends in Cancer, 2019, DNA sequencing and other genomics have been harnessed to study the genetic aberrations of human cancers to obtain information that aids in increasing precision in assigning drugs to patients. For instance, the development of targeted treatments which include small molecule therapeutics targeting specific gene mutations, such as imatinib for c-KIT gene mutation in Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors. In Aug 2020, AncestryHealth, based on Next Generation Sequencing, was launched by Ancestry to help customers understand their health and risk factors. It is a vital tool to screen genes associated with breast cancer, colon cancer, and blood disorders. Hence, the growing investment in genome sequencing research and development activities, along with the novel product launches, is expected to aid in the healthy growth of the studied segment over the forecast period.

Also, in October 2019, GENOMIKA, the leading genetic testing laboratory in Brazil, reached an agreement with Veritas Intercontinental to incorporate the whole genome and exome sequencing in its portfolio, along with all the services associated with these tests in the field of preventive medicine and clinical genetics.

Furthermore, its advantages over other techniques are known to boost the growth of the studied segment. For instance, in August 2020, the FDA approved the first liquid biopsy companion diagnostic that leverages Next-generation sequencing (NGS) technology to guide cancer treatment. The Guardant360 CDx assay promotes less invasive testing and the simultaneous mapping of several biomarkers of genomic alterations in the tumor.

On the basis of end user, the the genomics in cancer care market is classified into hospitals, government institutions and research facilities.

The hospitals segment are expected to dominate the genomics in cancer care market during the forecast period

Hospitals dominated genomics in the cancer care market. The factors, including well-resourced operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals.

Geographical Analysis

North America region holds the largest market share in the global Genomics in Cancer Care Market

North America region dominates the global genomics in cancer care market estimated for the largest market share in 2020, owing to the higher percentage rates of cancer disease and the initiatives taken by the government and other institutions related to genomics cancer. As per the Globocan 2020 report, an expected 2,281,658 new cancer cases were diagnosed in the U.S. in 2020, with nearly 612,390 deaths. In 2020, the most frequent cancers were prostate (209,512), and colon (101,809), breast (253,465), lung (227,875) in the U.S.

Also, several government bodies, like National Human Genome Research Institute, have been supporting research associated with human genome sequencing while financing research related to the genome's structure, purpose, and role in health and disease. Moreover, these organizations promote studies on the legal, ethical, and social implications of genome research.

Thus, owing to the growing burden of cancers in the country and increasing research activities about genomics, the market is anticipated to witness significant growth in the North American region.

On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to increased healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.

Competitive Landscape

The genomics in cancer care market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc, Affymetrix, Agilent Technologies, Roche Diagnostics, Cancer Genetics Inc., Beckman Coulter Inc., Bio-Rad Labs, Danaher Corporation, Sigma Aldrich Corporation, and Pacific Bioscience among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the genomics in cancer care market globally.

Roche Diagnostics

Overview: Roche Diagnostics is a diagnostic division of Hoffmann-La Roche which manufactures equipment and reagents, for research and medical diagnostic applications. ... Applied Science targets research settings in academia and pharmaceutical and biotechnology industries. Internally, it is organized into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland.

Product Portfolio: The Company's portfolio comprised of centralised and point of care solutions, custombiotech, diabetes care, molecular diagnostics & research among others.

Why Purchase the Report?

  • Visualize the composition of the genomics in cancer care market segmentation by product, application, technology, and end use highlighting the key commercial assets and players.
  • Identify commercial opportunities in genomics in cancer care market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of genomics in cancer care market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global genomics in cancer care market report would provide an access to an approx. 61 market data table, 56 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Genomics in Cancer Care Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Genomics in Cancer Care Market - Market Definition and Overview

3. Global Genomics in Cancer Care Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Technology
  • 3.4. Market Snippet by End Use
  • 3.5. Market Snippet by Region

4. Global Genomics in Cancer Care Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing geriatric population and advancement in technology will drive the market growth
      • 4.1.1.2. The rising in cancer and biotechnological advancements related to cancer care
    • 4.1.2. Restraints:
      • 4.1.2.1. High price associated with genomics devices will hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Genomics in Cancer Care Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Genomics in Cancer Care Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Genomics in Cancer Care Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Consumables
  • 7.4. Services

8. Global Genomics in Cancer Care Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diagnostics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Personalized Medicine
  • 8.4. Drug Discovery & Development
  • 8.5. Research

9. Global Genomics in Cancer Care Market - By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Genome Sequencing*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. PCR
  • 9.4. Microarray
  • 9.5. Nucleic Acid Extraction and Purification

10. Global Genomics in Cancer Care Market - By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers

11. Global Genomics in Cancer Care Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

12. Global Genomics in Cancer Care Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Global Genomics in Cancer Care Market- Company Profiles

  • 13.1. Roche Diagnostics*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AstraZeneca PLC
  • 13.3. Illumina, Inc
  • 13.4. Affymetrix
  • 13.5. Agilent Technologies
  • 13.6. Cancer Genetics Inc.
  • 13.7. Beckman Coulter Inc.
  • 13.8. Bio-Rad Labs
  • 13.9. Danaher Corporation
  • 13.10. Sigma Aldrich Corporation

LIST NOT EXHAUSTIVE

14. Global Genomics in Cancer Care Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us